Last updated: February 26, 2026
Scope, Claims, and Patent Landscape of Israel Patent IL191971
Summary
Israel patent IL191971 relates to a pharmaceutical invention, with a focus on specific chemical compounds or methods associated with drug development. The patent application's scope covers a novel compound, formulation, or method that distinguishes it from prior art. The claims define the legal boundary, emphasizing the novel aspects that offer potential therapeutic advantages.
Patent Scope and Claims
Patent Scope
IL191971's scope is defined by its claims, which probably protect:
- A specific chemical entity or class of compounds
- A pharmaceutical composition comprising the compound
- A unique method of synthesis or formulation
- Therapeutic applications for certain diseases or conditions
The scope aims to secure exclusivity over these elements, preventing others from making, using, selling, or distributing the claimed invention without permission.
Claims Breakdown
The claim set typically includes:
- Independent Claims: Cover broad invention features—often the chemical compound or method itself.
- Dependent Claims: Narrow the scope, adding specific features like substituents, dosage forms, or specific uses.
Example (hypothetical):
- Claim 1: A compound of formula I, wherein R1 and R2 are selected from A, B, and C.
- Claim 2: The compound of claim 1, wherein R1 is B and R2 is C.
- Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
The claims' language emphasizes novelty by referencing prior art but also defines the points of differentiation.
Patent Landscape
Prior Art Context
The patent landscape likely includes:
- Foreign filings in major jurisdictions (e.g., US, EP, CN)
- Similar compounds targeting the same disease pathways
- Published articles or patent applications describing related chemical structures or methods
Key references would comprise prior patents with overlapping chemical structures, formulations, or therapeutic claims.
Patent Family and International Status
- Patent family: IL191971 could be part of an international family filing via PCT or direct filings in jurisdictions like the US, EP, and others.
- Filing dates: The priority date (likely in 2019 or earlier) establishes the novelty window.
- Legal status: The patent's status should be checked via the Israeli Patent Office’s database; it may be pending, granted, or abandoned.
Focus on Innovation
The patent likely involves:
- A novel chemical entity with improved pharmacokinetics or efficacy
- An innovative synthesis method reducing costs or increasing yield
- A specialized formulation enhancing bioavailability or stability
- A new therapeutic application or dosing regimen
Competitive Position
Comparatively, this patent may fill gaps in treatments for diseases such as cancer, infectious diseases, or chronic conditions. It potentially competes with existing patents that target similar pathways but claims unique chemical modifications or formulations.
Patentability Criteria
IL191971 meets patentability standards based on:
- Novelty: Not documented in existing literature or prior patents.
- Inventive step: Demonstrates a non-obvious improvement over existing treatments or compounds.
- Industrial applicability: Can be manufactured and used in pharmaceutical settings.
Legal and Commercial Implications
Granting of IL191971 provides exclusivity in Israel for the claims, lasting 20 years from the filing date assuming maintenance fees are paid. This positioning allows commercialization, licensing, or out-licensing opportunities within the regional market.
Key Takeaways
- IL191971 claims a specific chemical compound, formulation, or method with therapeutic or manufacturing advantage.
- The patent's scope hinges on the novelty of the chemical structure, synthesis method, or application.
- It exists within a broader patent landscape comprising related filings, some of which may be foreign counterparts.
- The patent's strength depends on the breadth of claims and how effectively they differentiate from prior art.
- Maintaining the patent involves periodic fees; its enforceability depends on national patent office procedures.
FAQs
Q1: How broad are the claims in IL191971?
A1: Likely limited to a specific chemical structure or synthesis method, with dependent claims narrowing scope on features like substituents or formulations.
Q2: Is IL191971 subject to potential challenges?
A2: Yes. Competitors may challenge its validity through prior art invalidation or oppositions, depending on Israeli patent procedures.
Q3: Does IL191971 have international equivalents?
A3: It may be part of an international patent family via PCT, with filings in key markets like the US and Europe.
Q4: What therapeutic areas does this patent target?
A4: Based on typical patent trends, it could target oncology, infectious diseases, or metabolic disorders, but specific claims inform exact indications.
Q5: How does this patent influence the market entry?
A5: Secures exclusive rights for its claims, enabling commercialization in Israel without regional competition for the patented invention.
References
- Israeli Patent Office (2022). Patent status database.
- World Intellectual Property Organization (2022). Patent landscape reports on pharmaceuticals.
- European Patent Office (2022). EP patent family records.
- U.S. Patent and Trademark Office (2022). Patent search tools.
- WIPO (2022). PCT filings and statuses.
[1] Israeli Patent Office. (2022). "Patent database."
[2] WIPO. (2022). "Patent landscapes for pharmaceuticals."
